Posted by Michael Wonder on 14 Oct 2025
MannKind announces US FDA accepts for review its supplemental biologics license application for inhaled ansulin (Afrezza) in children and adolescents aged 4-17 years living with diabetes
13 October 2025 - MannKind Corporation today announced that the US FDA has accepted the supplemental biologics license application seeking approval for Afrezza (insulin human) inhalation powder in children and adolescents living with type 1 or type 2 diabetes.
The application has been assigned a PDUFA target action date of 29 May 2026.
